# Dayton Misfeldt

> Dayton Misfeldt is a Series B investor at Decheng Capital backing Biotechnology and Pharmaceutical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Decheng Capital](https://shizune.co/investors/profile/decheng-capital)
- Location: San Francisco, United States
- Total investments: 4
- Last investment: Jul 2013
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/dayton-misfeldt/47/5a8/90

Dayton Misfeldt is a Series B investor at Decheng Capital in San Francisco focused on Biotechnology and Pharmaceutical. Dayton Misfeldt

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Pharmaceutical | 3 | 75% |
| Health Care | 2 | 50% |
| Beauty | 1 | 25% |
| Medical | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 25% |
| Series C | 1 | 25% |
| Private Equity | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TRIA Beauty | TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $45.5M | Private Equity | Jul 09, 2013 |  |
| NextWave Pharmaceuticals | NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology. | $45M | Series C | Jan 11, 2011 |  |
| Sunesis Pharmaceuticals | Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment toinnovation. | $43.5M | Post-IPO Equity | Apr 07, 2009 |  |
| Presidio Pharmaceuticals | Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, NexusMedical Partners, and Sagamore Bioventures LLC. | $26M | Series B | Aug 29, 2007 |  |

4 of 4 investments shown.

## Co-investors
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 2 deals together
- [Panorama Capital](https://shizune.co/investors/profile/panorama-capital) — VC Fund, 2 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [Athyrium Capital Management LP](https://shizune.co/investors/profile/athyrium-capital-management) — VC Fund, 1 deal together
- [DeNovo Ventures](https://shizune.co/investors/profile/denovo-ventures) — VC Fund, 1 deal together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 1 deal together

## About Decheng Capital

VC Fund · Menlo Park, United States

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

5 contacts available at Decheng Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Zabrowski | Venture Partner | https://shizune.co/investors/profile/dan-zabrowski |
| Min Cui | Founder and Managing Director | https://shizune.co/investors/profile/min-cui |
| Dayton Misfeldt | Partner | https://shizune.co/investors/profile/dayton-misfeldt |
| Nathan Pliam | Partner | https://shizune.co/investors/profile/nathan-pliam |
| Victor Tong | Partner | https://shizune.co/investors/profile/victor-tong |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Dayton Misfeldt invest in?

Dayton Misfeldt invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dayton Misfeldt last invest?

The most recent investment recorded for Dayton Misfeldt closed in Jul 2013. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co